CAS No. |
96996-50-8 |
中文名称 |
(S)-2-氨基-N-[((6S,7R,9R,14aS,15R)-7-氰基-1-羟基-2,11-二甲氧基-3,12,16-三甲基-10,13-二氧代-6,7,9,10,13,14,14a,15-八氢-5H-6,15-亚氨基苯并[4,5]氮杂辛并[1,2-b]异喹啉-9-基)甲基]丙酰胺 |
英文名称 |
(S)-2-amino-N-(((6S,7R,9R,14aS,15R)-7-cyano-1-hydroxy-2,11-dimethoxy-3,12,16-trimethyl-10,13-dioxo-6,7,9,10,13,14,14a,15-octahydro-5H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinolin-9-yl)methyl)propanamide |
别名 |
cyanosafracin B;Cyanoquinonamine;CBR28-1;Propanamide, 2-amino-N-[[(6S,7R,9R,14aS,15R)-7-cyano-6,7,9,10,13,14,14a,15-octahydro-1-hydroxy-2,11-dimethoxy-3,12,16-trimethyl-10,13-dioxo-6,15-imino-5H-isoquino[3,2-b][3]benzazocin-9-yl]methyl]-, (2S)-;(2S)-2-Amino-N-[[(6S,7R,9R,14aS,15R)-7-cyano-6,7,9,10,13,14,14a,15-octahydro-1-hydroxy-2,11-dimethoxy-3,12,16-trimethyl-10,13-dioxo-6,15-imino-5H-isoquino[3,2-b][3]benzazocin-9-yl]methyl]propanamide;inhibit,Inhibitor,Cyanosafracin B;Cyanosafracin B, 10 mM in DMSO |
标准英文名 |
(S)-2-amino-N-(((6S,7R,9R,14aS,15R)-7-cyano-1-hydroxy-2,11-dimethoxy-3,12,16-trimethyl-10,13-dioxo-6,7,9,10,13,14,14a,15-octahydro-5H-6,15-epiminobenzo[4,5]azocino[1,2-b]isoquinolin-9-yl)methyl)propanamide |
分子式 |
C29H35N5O6 |
分子量 |
549.63
|
精确分子量 |
549.26
|
SMILES |
COC1=C(C)C(=O)C2=C(C1=O)[C@H](CNC(=O)[C@H](C)N)N1[C@@H](C#N)[C@@H]3CC4=C(C(O)=C(OC)C(C)=C4)[C@H]([C@@H]1C2)N3C |
标准SMILES |
CN1[C@H]2[C@@H]3CC4=C([C@H](CNC(=O)[C@H](C)N)N3[C@@H](C#N)[C@@H]1CC1C=C(C)C(OC)=C(O)C=12)C(=O)C(OC)=C(C)C4=O |
用途 |
Cyanosafracin B is a key starting material for the synthesis of the anticancer drug trabectedin (ET-743), which is primarily indicated for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma in patients who have previously received anthracycline-containing therapy. |
InChIKey |
BHINEHROXMLHMV-BVRLQDJESA-N |